Robecosam AG reduced its stake in shares of Agilent Technologies Inc (NYSE:A) by 21.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 485,515 shares of the medical research company’s stock after selling 129,191 shares during the quarter. Agilent Technologies makes up approximately 2.2% of Robecosam AG’s portfolio, making the stock its 7th largest position. Robecosam AG’s holdings in Agilent Technologies were worth $32,748,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. lifted its stake in Agilent Technologies by 8.1% in the fourth quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock valued at $1,718,808,000 after acquiring an additional 1,912,186 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Agilent Technologies by 325.0% in the fourth quarter. Renaissance Technologies LLC now owns 2,370,200 shares of the medical research company’s stock valued at $158,732,000 after acquiring an additional 1,812,500 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Agilent Technologies by 145.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,726,929 shares of the medical research company’s stock valued at $115,652,000 after acquiring an additional 1,023,099 shares during the last quarter. TimesSquare Capital Management LLC acquired a new stake in Agilent Technologies in the third quarter valued at approximately $58,550,000. Finally, Bank of Montreal Can lifted its stake in Agilent Technologies by 187.3% in the fourth quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock valued at $49,693,000 after acquiring an additional 483,721 shares during the last quarter.
In related news, insider Mark Doak sold 15,567 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $68.00, for a total transaction of $1,058,556.00. Following the transaction, the insider now owns 71,104 shares of the company’s stock, valued at $4,835,072. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael R. Mcmullen sold 21,850 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,638,750.00. Following the transaction, the chief executive officer now directly owns 324,687 shares in the company, valued at approximately $24,351,525. The disclosure for this sale can be found here. Insiders have sold 102,970 shares of company stock worth $7,340,641 in the last ninety days.
Agilent Technologies Inc (A) opened at $71.13 on Monday. Agilent Technologies Inc has a 52-week low of $51.48 and a 52-week high of $75.00. The company has a market cap of $22,954.88, a P/E ratio of 28.45, a PEG ratio of 2.38 and a beta of 1.30. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.23 and a quick ratio of 2.78.
Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 14th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.08. Agilent Technologies had a net margin of 4.25% and a return on equity of 17.70%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same quarter in the previous year, the firm posted $0.53 earnings per share. sell-side analysts forecast that Agilent Technologies Inc will post 2.67 EPS for the current year.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.